Figure 1
From: Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes
*P < 0.05, HOX versus DOX, HOX versus medium if present; **P < 0.05, HOX versus DOX, HOX versus medium, HOX versus HDFTr.
Figure 1 | Breast Cancer Research